US 11,718,878 B2
Exosome profiling for diagnosis and monitoring of vasculitis and vasculopathies including Kawasaki disease
Michael Portman, Mercer Island, WA (US)
Assigned to Seattle Children's Research Hospital, Seattle, WA (US)
Appl. No. 16/640,323
Filed by Seattle Children's Hospital, Seattle, WA (US)
PCT Filed Aug. 20, 2018, PCT No. PCT/IB2018/056292
§ 371(c)(1), (2) Date Feb. 19, 2020,
PCT Pub. No. WO2019/038660, PCT Pub. Date Feb. 28, 2019.
Claims priority of provisional application 62/548,330, filed on Aug. 21, 2017.
Prior Publication US 2020/0248260 A1, Aug. 6, 2020
Int. Cl. C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/178 (2013.01); G01N 2800/328 (2013.01)] 18 Claims
 
1. A method for treating, inhibiting or ameliorating Kawasaki disease (KD) in a human subject, comprising:
(i) detecting a KD biomarker in a biological sample from a human subject comprising:
(a) providing a population of nucleic acids prepared from the biological sample, wherein the biological sample is enriched for CD31+ exosomes,
(b) hybridizing a probe with the population of nucleic acids, wherein the probe is capable of detecting linc-ZNF337-1, and
(c) detecting the presence of linc-ZNF337-1 in the biological sample,
(d) identifying the subject as having KD when linc-ZNF337-1 is present; and
(ii) administering a therapy for the KD to the subject having KD, wherein the therapy comprises an effective amount of a composition selected from the group consisting of an intravenous immunoglobulin, aspirin, and a corticosteroid.